Skip to content
Martina Stamm-Fibich

Martina Stamm-Fibich

Not rated

Martina Stamm-Fibich (born 23 April 1965 in Erlangen) is a German politician of the Social Democratic Party of Germany (SPD) who was a member…

  • Facts0
  • Drivers0
  • Indicators0

Expert article

Martina Stamm-Fibich (born 23 April 1965 in Erlangen) is a German politician of the Social Democratic Party of Germany (SPD) who was a member of the Bundestag from 2013 to 2025. She held the seat on the SPD state list in Bavaria for the Erlangen constituency, where the Christian Social Union in Bavaria kept the direct mandate. A marketing and communications manager by occupation, she worked from 1989 to 2013 in the healthcare business of Siemens in Erlangen, most recently as a works-council member released from other duties, and the Bundestag's register of members' interests records a right to return to that employment.

She gained the mittlere Reife in 1981, served an apprenticeship as a law-firm clerk (Rechtsanwaltsfachangestellte) from 1981 to 1983, and worked in that occupation until 1985. From 1986 to 1989 she assisted the management of a medium-sized service company. The parliamentary biographies, which the Bundestag says rest on members' own statements, describe her as divorced with two children and, in the 19th electoral term, as Reformed Protestant (evangelisch-reformiert). In Middle Franconia those notes list her as treasurer of the SPD district organisation, deputy chair of the SPD in Erlangen-Höchstadt, and an honorary member of the Erlangen-Höchstadt district council.

She was a full member of the Health Committee and of the Petitions Committee. In June 2018 the SPD parliamentary group named her its patient representative. She called for a compensation fund where harm to patients was morally compelling but not legally recoverable, pointing to the Contergan and Duogynon cases, and she also pressed for plainer information on the risks of medicines and for the electronic patient record. In the 19th term she was deputy chair of the Petitions Committee. The Bundestag reported on 15 December 2021 that the committee had elected her chair, with 28 votes in favour and one against, in the presence of Vice-President Yvonne Magwas; she succeeded Marian Wendt, and the committee then had 31 members. For the 20th term her biography lists her as the SPD rapporteur on medicines (AMNOG reform, vaccines and diagnostics), on reform of joint self-government through the Federal Joint Committee, on medical devices, on patient interests and the independent patient-counselling service, on health-related consumer protection, and on therapeutic appliances and aids. She was also a substitute member of the Committee on Foreign Affairs and of the Committee on Economic Cooperation and Development.

In the Erlangen constituency the SPD share of first votes was 26.3 percent (35,377) in 2013, 21.0 percent (30,965) in 2017 and 20.7 percent (32,036) in 2021, while the CSU share moved from 48.5 percent to 42.7 percent and then to 35.1 percent. The Bundestag recorded that on 26 September 2021 she again entered through the Bavarian list after receiving 20.7 percent of the first votes. She stood again at the 2025 federal election and was not re-elected. In the Erlangen constituency, renumbered 241, the federal returning officer recorded an SPD first-vote share of 17.3 percent (28,003 votes); Konrad Körner of the CSU won the seat with 35.9 percent, ahead of Paulus Guter of Alliance 90/The Greens with 18.2 percent. In February 2026 she became head of the political staff of the Siemens company health-insurance fund (Siemens-Betriebskrankenkasse), with responsibility for the fund's political line and for talks with decision-makers in the federation and the Länder. The same report described her, among pharmacists, as a critic of the governing coalition's idea of a "pharmacy without a pharmacist", in which pharmaceutical-technical assistants would have stood in for an absent pharmacist.

Early life and career before parliament

Childhood, schooling and training

Martina Stamm-Fibich was born on 23 April 1965 in Erlangen, according to the member biographies published by the German Bundestag. The Bundestag states that these biographical entries rest on the member's own information. They record that she obtained the Mittlere Reife, the intermediate secondary-school certificate, in 1981, and they list no university study. In a December 2013 interview published by the Social Democratic Party of Germany Bundestag group, she said she was one of the few members of the group who had not studied and who did not come from an academic household.

From 1981 to 1983 she trained as a Rechtsanwaltsfachangestellte, a law-firm clerk, and from 1983 to 1985 she worked in that occupation. Her 2013 profile on the candidate-comparison site Wen wählen? gave the same training, abbreviated there as "RA-Fachangestellte". From 1986 to 1989, the Bundestag biographies state, she was assistant to the management of a medium-sized service company; they do not name the firm.

Work at Siemens Healthcare

Those biographies place her from 1989 to 2013 at Siemens AG, Healthcare Sector, in Erlangen, last as a freigestellte Betriebsrätin — a member of the works council released from her ordinary job. In the statutory register of members' interests for the 18th electoral term, the activity before she joined the Bundestag was entered as marketing and communications manager and released works councillor at Siemens AG, Erlangen. During the 2013 campaign Wen wählen? listed her occupation as released works councillor, and in December 2013 she told the SPD group that she had worked for years as a works councillor at Siemens and that she came from medical technology.

Under section 38 of the Works Constitution Act, establishments above set workforce thresholds must release a minimum number of elected works-council members from their jobs, in full or in part, so that they can carry out council duties; collective agreements or works agreements may set different release rules. Stamm-Fibich said in the 2013 interview that the Siemens role made labour and social policy her main interest in parliament, because she could contribute practical experience, and that reconciling employment with family life was a cause she had already pursued in local politics. She also said a place on the health committee appealed to her because of that medical-technology background, and she described Erlangen as Germany's "Medical Valley". The Bundestag biographies additionally list membership of IG Metall; like the rest of the narrative biography, that detail is her own statement to parliament.

Siemens's museum history traces the Erlangen medical-technology works to a workshop opened in 1877, records that from 1964 for about fifty years the central administration stood in a high-rise in Erlangen, and states that in 2000 a factory and administration building of 39,000 square metres opened at Röthelheimpark to build magnetic-resonance scanners and other equipment. The same account dates the founding of Siemens Healthcare GmbH to 1 May 2015 and the presentation of the Siemens Healthineers brand to a year later; Siemens Healthineers AG was listed in Frankfurt on 16 March 2018, and a new Erlangen headquarters begun in 2016 was finished in 2018, when about 1,000 employees moved out of the former administration building. By the 20th electoral term the interests register named her former post as marketing and communications manager and works councillor at Siemens Healthcare GmbH, Erlangen, and recorded a right of return.

Party membership and local office

Joining the SPD and first mandates

Bundestag biographies do not state when Martina Stamm-Fibich joined the Social Democratic Party of Germany. The earliest dated party office in the regional press is 25 April 2013, when the SPD Kreisverband Erlangen-Höchstadt, meeting in Gremsdorf, confirmed her and Christian Pech — both from Möhrendorf — as deputy chairs under Fritz Müller of Heroldsberg. Pech, who also led the SPD group on the district council, said Müller had held the chair for ten years.

The Rathaus in the centre of Möhrendorf.

At the local elections in Bavaria on 16 March 2014 she stood for that Kreistag and for the Möhrendorf Gemeinderat. The district returning officer's preliminary result of 18 March placed her third on the SPD list for the 60-seat Kreistag, with 23,528 votes, behind German Hacker and Pech; the list won 13 seats. She was listed as a marketing and communications manager living at Amselweg 23 in Möhrendorf.

She took the municipal seat as well. On 1 February 2016 she asked to be released, writing that dates from her Bundestag mandate and the council's sittings could no longer be combined. On 16 February the council agreed, 14 votes to none, and seated Monika Bohnert, the third SPD successor named by the election committee on 16 March 2014. Disclosures for her Bundestag mandates record the Möhrendorf seat as ending on 31 January 2016, and an unpaid Kreistag seat during the 2013–2017, 2017–2021 and 2021–2025 terms.

District council and party posts

In the Kreistag election of 15 March 2020 she led the SPD list with 26,066 votes. The election committee's final result of 28 April gave the list eight of 60 seats. The archived biography for the 20th Bundestag, based on her own statements, lists her as honorary Kreisrätin, deputy chair of the SPD Erlangen-Höchstadt — the page once writes "Höchststadt" — and treasurer of the SPD Bezirk Middle Franconia, and repeats an unpaid Kreistag seat.

She became Kassiererin of the Bezirk on 19 July 2014, when Carsten Träger succeeded Christa Naaß as chair. At the Bezirksparteitag in Nuremberg reported on 12 July 2016 she remained treasurer while Träger was re-elected with 89.7 percent of the votes cast. On 8 May 2025, 51 delegates at the Hallerhof in Buckenhof confirmed Müller as chair and Stamm-Fibich and Pech as deputies for two years. For the congress of 15 November 2025 at Nuremberg's Karl-Bröger-Zentrum she was presented for co-chair of the Bezirk, not for treasurer, while the booklet still listed the deputy chair and the Kreistag seat. The executive published afterwards names Victor Strogies as treasurer and does not include her; the page says that board was last elected on 15 November 2025.

On 8 March 2026 she was returned to both councils. The final district count gave her 20,647 votes; the SPD list took 13.8 percent and eight of 60 seats. In Möhrendorf the preliminary result gave the SPD two of 16 seats. She was first of the two, with 970 votes, ahead of Philipp Plate on 724; the ballot called her a political adviser and Kreisrätin, born in 1965. The SPD branch for Möhrendorf and Kleinseebach lists her as chair of its council group and as a member of the building, climate, environment and property committee.

Bundestag candidacies and results

Elections of 2009, 2013 and 2017

Stamm-Fibich first stood for the Bundestag on 27 September 2009, in constituency 242, Erlangen. She was the direct candidate of the Social Democratic Party of Germany (SPD) and 38th on the party's state list in Bavaria. The constituency result names Stefan Müller of the Christian Social Union in Bavaria (CSU) as the leading candidate, with 60,685 first votes (45.12 percent). Stamm-Fibich received 32,269 (23.99 percent). Turnout was 76.64 percent of 177,261 eligible voters, and the SPD's second-vote share in the constituency was 20.96 percent.

The state statistical office's account of the election records eight women and eight men elected for the SPD among Bavaria's 91 Bundestag seats. Thirty-eighth on the list, she did not win a seat.

In 2013 she was 18th on the Bavarian SPD list and again the party's candidate in Erlangen. The federal returning officer's final result gave the SPD 35,377 first votes (26.3 percent) and the CSU 65,151 (48.5 percent); the city's constituency table names Stamm-Fibich and Müller for those totals. Second votes were 24.3 percent for the SPD and 41.7 percent for the CSU, and turnout was 75.3 percent of 179,506 eligible voters. The state report lists 22 SPD members from Bavaria, all elected on the state list and none in a constituency, through list place 22. Place 18 fell inside that allocation. A later Bundestag account dates her membership from 2013.

For 2017, the SPD's Bavarian delegate meeting on 10 December 2016 placed her 14th and named her for constituency 242. She received 30,965 first votes (21.0 percent) against Müller's 62,767 (42.7 percent). The SPD's second-vote share in the constituency was 17.4 percent, and turnout was 81.9 percent of 180,730 eligible voters. The state returning officer's final result gives the SPD 18 Bavarian seats, list places 1 to 18, with place 19 the first successor not elected. She was returned on the list.

The 2021 election

On 26 September 2021 she again faced Müller in constituency 242, from 18th place on the SPD list. The federal result was 54,223 first votes (35.1 percent) for the CSU and 32,036 (20.7 percent) for the SPD; Erlangen's table assigns the CSU figure to Müller and the SPD figure to Stamm-Fibich. Alliance 90/The Greens received 29,923 first votes (19.4 percent). Second votes split 28.9 percent to the CSU, 20.2 percent to the Greens and 19.5 percent to the SPD. Turnout was 83.0 percent of 187,299 eligible voters.

The Bavarian returning officer's notice of the final result includes her among those elected on the SPD state list. The notice names 23 SPD members, each marked as elected from the list rather than in a constituency. A Bundestag text of 15 December 2021 says that the then 56-year-old entered again by way of the Bavarian list with 20.7 percent of the first votes, represented Erlangen, and had sat in the Bundestag since 2013.

The 2025 election

At the election of 23 February 2025 the constituency was numbered 241. Müller, who had won it in 2021, did not stand. On the SPD's adopted Bavarian list she was 26th, and the list named her for constituency 241. She received 28,003 first votes (17.3 percent). Konrad Körner of the CSU was elected with 57,971 (35.9 percent), and Paulus Guter of the Greens took 29,337 (18.2 percent). The SPD's second votes in the constituency were 22,446 (13.9 percent), against 33.7 percent for the CSU and 18.0 percent for the Greens. Turnout was 86.8 percent of 186,938 eligible voters.

Map of Bundestag constituency 241 Erlangen.

The Federal Elections Act as amended in 2023, and in force for this election, fixes the Bundestag at 630 members, distributed by each party's second votes, and does not add overhang or compensatory seats. A party's constituency candidate is elected only with the most first votes and a seat under the second-vote coverage procedure; seats still due to a state list are then filled in list order, passing over anyone already elected in a constituency. Third in Erlangen, Stamm-Fibich had no plurality from which a constituency seat could follow. In Bavaria the SPD was allocated 14 seats, all of them from the state list, while the CSU took the 44 constituency seats allocated to the state. Place 26 was beyond the SPD's 14. She stood again and was not returned, and her membership, which had run from 2013 to 2025, ended.

Offices in the Bundestag

Health Committee and rapporteurships

Martina Stamm-Fibich was a full member of the Bundestag Committee on Health in the 18th, 19th and 20th electoral terms. The standing committees of the 18th Bundestag constituted themselves on 15 January 2014. The Health Committee then had 37 full members — 18 from the CDU/CSU, eleven from the SPD, and four each from the Left and the Greens — and elected Edgar Franke (SPD) as chair in succession to Carola Reimann. Stamm-Fibich was one of the eleven SPD members. The archived biography for that term also lists her as a full member of the Petitions Committee and as a substitute member of the Committee on Family Affairs, Senior Citizens, Women and Youth.

The Health Committee of the 19th Bundestag held its constituent sitting on 31 January 2018, with Vice-President Petra Pau presiding. The committee then had 41 full members. Erwin Rüddel (CDU/CSU) was chosen chair; Franke had chaired it in the previous term. Stamm-Fibich was again a full member, while Sabine Dittmar was the SPD group's spokesperson (Obfrau). The biography for the 19th term records that Health Committee seat together with a full seat on the Petitions Committee. She remained a full member of the Health Committee in the 20th term. At that committee's opening, twelve of the full members were from the SPD, Stamm-Fibich among them.

The Bundestag's biography for the 20th term, which rests on members' own disclosures, describes her as the SPD rapporteur for medicines — the reform of the AMNOG framework, vaccines and diagnostics — for joint self-government, including reform of the Federal Joint Committee (G-BA), and for medical devices, patient interests and counselling (the Independent Patient Counselling service, UPD), health-related consumer protection, and therapeutic appliances and aids (Heil- und Hilfsmittel). Those were subject briefs inside the SPD group, not chairs of the Health Committee.

Patient representative of the SPD group

The patient brief was a separate appointment by the SPD Bundestag group, not a seat on a Bundestag committee. On 24 April 2018 the group named Heike Baehrens its commissioner for nursing and for the concerns of patients, a combined brief. On 7 June 2018 Deutsches Ärzteblatt reported that Stamm-Fibich had become the group's patient representative (Patientenbeauftragte), and noted that she had sat on the Health Committee and the Petitions Committee since 2013. The post is an internal assignment of the parliamentary group. It is distinct from the statutory office of patient commissioner of the federal government.

The group named its commissioners again on 15 February 2022 and once more appointed Stamm-Fibich patient representative for the 20th term. The Bundestag biography for that term continues to describe her as the SPD group's patient representative since 2018.

Petitions Committee and other seats

On 15 December 2021 the Petitions Committee elected her chair by 28 votes to one, with Bundestag Vice-President Yvonne Magwas (CDU/CSU) present. The committee then had 31 members. She succeeded Marian Wendt (CDU/CSU), who had chaired it in the previous term and had not stood again for the Bundestag. The committee had already constituted itself, then with 19 members, on 11 November 2021, when Magwas held the chair temporarily.

She had already been a full member of the committee in the 18th term. In the 19th term the biography lists her as deputy chair as well as a full member. A Bundestag notice of 30 May 2018, before the handover of the committee's report for 2017, named Wendt as chair and Stamm-Fibich as deputy chair. When the report for 2018 was presented to Bundestag President Wolfgang Schäuble in May 2019, the parliament's caption again identified her as deputy chair.

Her other recorded Bundestag seats were substitutes. In the 19th term she was a substitute member of the Committee on Economic Affairs and Energy and of the Subcommittee on Global Health. In the 20th term she was a substitute on the Committee on Economic Cooperation and Development and on the Committee on Foreign Affairs. In January 2022 the SPD group also elected her to its extended executive (erweiterter Fraktionsvorstand), one of 25 members announced on 13 January.

Medicines, devices and statutory health insurance

Benefit assessment, prices and the AMNOG framework

The Bundestag biography of Stamm-Fibich, based on her own information, listed her as the Social Democratic Party of Germany (SPD) rapporteur for medicines, including reform of the Pharmaceutical Market Restructuring Act (Arzneimittelmarktneuordnungsgesetz, AMNOG), and for joint self-government, including reform of the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA). Under section 35a of Book V of the Social Code, the G-BA assesses the additional benefit of reimbursable medicines with new active substances against an appropriate comparator. For an orphan drug authorized under European Union Regulation No 141/2000, that additional benefit is deemed proven by the authorization unless twelve-month turnover with statutory health insurance (gesetzliche Krankenversicherung, GKV) exceeds €30 million; the statute applies the line, among other cases, to products that had already crossed it on 1 December 2022, and below it the usual comparative evidence need not be filed. Under section 130b, the agreed reimbursement amount applies from the seventh month after a new active substance is first marketed.

In 2022 the rules were changed inside the Act on the Financial Stabilization of Statutory Health Insurance (GKV-Finanzstabilisierungsgesetz) of Federal Minister of Health Karl Lauterbach, passed by the Bundestag on 20 October. The ministry said the law would close a deficit it put at €17 billion without cutting benefits, make medicines with no additional benefit cheaper, and change the pricing of new drugs with no or only a minor additional benefit, with a higher manufacturer rebate for 2023 and a longer price moratorium. Three days earlier, on a podcast of the Federal Association of Pharmaceutical Manufacturers, Stamm-Fibich said she would have preferred a statute of its own for AMNOG. At the association’s meeting on 27 September she had called the previous grand coalition’s record “our mistake”: in four years, she said, “we never turned a single screw on the income side,” while passing laws both sides knew would cost money.

Shortages and supply legislation

Off-patent shortages produced a sharper difference with Lauterbach. On 22 December 2022 Tagesspiegel Background reported that Stamm-Fibich, as the SPD group’s medicines rapporteur, had distanced herself from key points he had issued on supply gaps. In the article’s account, she regarded parts of the proposals as “utopian” and wanted a real-time view of which pharmacies, wholesalers and hospitals held which products.

At the first reading on 24 May 2023 of the draft Act to Combat Supply Shortages of Off-Patent Medicines and to Improve the Supply of Children’s Medicines (Arzneimittel-Lieferengpassbekämpfungs- und Versorgungsverbesserungsgesetz, ALBVVG), she defended the coalition text as a bundle—stockpiling, reimbursement, steering of supply, reporting duties and shortage management in pharmacies—rather than a single remedy for broken chains, plant shutdowns and a concentrated global market. Higher prices for children’s medicines and some other substances were meant to stop the number of manufacturers falling further. In discount-contract tenders, sickness funds would have to obtain at least half of the medicines from the European Economic Area, “even if, as we know, it becomes more expensive.” Wider manufacturer reporting mattered to her personally, she said, because shortages could be managed only with data for an early-warning system; the bill would also give pharmacies more flexible dispensing rules and less bureaucracy. Location policy, she added, remained economic policy “and cannot be performed by the GKV.”

The act appeared in the Federal Law Gazette on 26 July 2023 and took effect on 27 July. The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) says it strengthened the institute and its shortage advisory board, required a list of medicines needed especially for children up to twelve, and added manufacturer reports, an early-warning system and scrutiny of concentration in off-patent markets for supply-critical substances. In October 2024, at an evening of the wholesale association Phagro, Stamm-Fibich said the ALBVVG had not solved shortages and that the information gaps remained a task for politics. The wholesalers’ Service Level Indicator, reported weekly since the end of 2023, was in her view a useful early warning for the BfArM, but she would still prefer Danish practice, where one can see at any time which hospital and which pharmacy holds a medicine. The law, she said, was a first step but “certainly not the last word.”

Devices, aids, the G-BA and rare diseases

The rapporteur brief also covered medical devices. In April 2024 the Pharmazeutische Zeitung reported a Bundestag debate on a CDU/CSU motion to secure device supply. The paper wrote that, under the European Union Medical Device Regulation, certification in Germany took about eighteen months on average and that products were leaving the market. Stamm-Fibich treated part of the motion as already met: rules for niche products and national exceptional authorizations existed, and Germany had pressed for longer transition periods. Anything further, she said, the federal government could not deliver. The motion was sent to the Health Committee.

For medical aids (Hilfsmittel), section 127 of Book V requires sickness funds to contract by negotiation, to let every suitable provider negotiate, and to secure enough aids free of extra payment, with product quality, advice and care close to home. In March 2025 Stamm-Fibich told Deutsches Ärzteblatt that she was still glad the tenders had been ended—a fight she dated to 2016, with the then federal patient representative Karl-Josef Laumann—because “people were in some cases terribly supplied.” In the same interview she described joint self-government as often closed to members of parliament: decisions over billions were taken, she said, without MPs receiving the relevant information, and even public-law sickness funds would treat figures as a trade secret.

A March 2022 interview from the initiative change4RARE was titled on the claim that health-system reform must not come at the expense of patients with rare diseases. Its notes introduced her as the SPD rapporteur for rare diseases and G-BA reform, as well as for aids, medicines, vaccination, devices and patient rights.

Pharmacies, counselling and patient rights

Pharmacies and professional rules

Pharmacy policy in the SPD Bundestag group was Dirk Heidenblut’s brief; Martina Stamm-Fibich’s rapporteurships were medicines and medical aids. In June 2024 the Federal Ministry of Health, under Karl Lauterbach, circulated a draft Pharmacy Reform Act, citing staff shortages, that would have let a branch-network pharmacy open with an experienced pharmaceutical technical assistant present, if a pharmacist in the network was available by video and the manager was on site at least eight hours a week. Talks with pharmacists, and Heidenblut’s account of an “Apotheke ohne Apotheker”, convinced her that a draft she had first thought well meant should not pass in that form. She still accepted branch pharmacies with lower requirements, and better pay and promotion for assistants, but she said she stood by pharmacy as a free profession and by the Mehrbesitzverbot. Under the Pharmacy Act a licence covers one pharmacy and at most three branches, and it is personal to the pharmacist named in it. She said too little was earned in the pharmacy. She opposed a general rise in the fixed fee, which would also reward large profitable firms, and she dropped the draft’s cut in the percentage margin from 3 to 2 per cent, because smaller pharmacies struggled to pre-finance expensive medicines. She preferred higher emergency-duty pay and a stepped fee on the first 10,000 prescription packs.

In October 2024 she said she was not optimistic the bill would come soon. Georg Kippels of the CDU called a pharmacy without a pharmacist on the premises an attack on the profession, and one the FDP would not accept. She argued for telepharmacy between doctor and pharmacist at night and in emergencies, and said mail order, though unlikely to disappear, could not cover that local duty. By February 2025 the Pharmazeutische Zeitung treated the original bill as having been avoided partly through resistance inside Lauterbach’s party, including hers; a year later it remembered her as a critic of the “pharmacy without a pharmacist”.

Patient counselling, records and rights

From 2018 she was the SPD group’s patient representative. Her Bundestag biography, drawn from her own information, names her rapporteur for patient interests, the Unabhängige Patientenberatung Deutschland (UPD), and health-related consumer protection. She backed a compensation fund in the coalition agreement of the time, contrasting payments after the Contergan scandal with the lack of compensation in the Duogynon cases, and she wanted clearer warnings on drug risks and an electronic patient record that would make treatment easier to follow.

The UPD had been awarded by tender, latterly for seven years at a time. The government bill said neutrality, independence and continuity were repeatedly in doubt, and the coalition agreement had promised a lasting foundation, kept at a distance from the state and centred on the main patient organisations. Stamm-Fibich was the SPD rapporteur. When the law passed on 16 March 2023 she called the foundation a milestone, and said the tender model had left independence in doubt, money flowing to the operator’s parent, and breaks in the service. Advice in person was to be required in every Land, and annual funding was to rise from the 10 million euros she named to the 15 million the statute assigns from 2024 to statutory and private insurers. The health committee adopted the amended bill with the votes of the SPD, Alliance 90/The Greens and the FDP, against the CDU/CSU and the AfD; Die Linke abstained.

Hubert Hüppe of the CDU/CSU said the bill had come too late, that sickness-fund finance, including what he called a veto over the budget, undermined independence, and that advisers were already leaving. In September 2023, answering warnings of a collapse from the Left and the CDU/CSU, she said she had spent seven of her ten years on the health committee on the UPD, that the foundation deed had been filed on 15 September, and that she still expected a start on 1 January 2024. As a former works councillor she asked that staff be treated fairly, called a December pause the last of its kind, and said another solution would be needed if advice then failed. In March 2025 she said she was glad that, after a difficult birth, a foundation existed, and hoped it would soon work as members of parliament had intended.

That October, on Deutschlandfunk, she defended the opt-out record insurers were to open from the start of 2025 unless a person objected: illnesses and intolerances in one encrypted file, which patients would control, in a country she said was behind Denmark and Austria. The Munich psychiatrist Andreas Meißner said compulsory transmission would break medical confidentiality, cost about 10 billion euros, and expose data to hacking. She has also argued for a pharmacy receipt listing a medicine’s full price, so patients can see what statutory insurance pays.

The Petitions Committee in practice

Procedure, caseload and reports

In the 19th Bundestag Stamm-Fibich was deputy chair of the Petitions Committee under Marian Wendt (CDU/CSU). Article 17 of the Basic Law lets anyone submit a written request or complaint; the committee handles federal legislation and federal administration, takes a government statement, and recommends a decision to the House. Until 1 July 2024 a published petition with 50,000 co-signatures within four weeks was heard in public. Most cases were individual complaints about official decisions rather than proposals for new law.

The 2020 report, which Wendt presented on 9 June 2021, recorded 785 more petitions than in 2019. Five public sittings covered 14 submissions, including a ban on mail-order sales of prescription medicines and coronavirus aid for the self-employed.

As chair she gave the annual reports to Bundestag President Bärbel Bas and introduced them in the plenary. The 2021 report (printed paper 20/2200), handed over on 22 June 2022, listed 11,667 petitions, 2,647 fewer than in 2020. Of these, 2,876 concerned the Federal Ministry of Health, which Stamm-Fibich called an unprecedented health caseload, much of it about the COVID-19 pandemic. For 2022 (printed paper 20/7100), presented on 21 June 2023, intake rose by 1,575 to 13,242: health remained largest but fell to 2,093, while foreign-policy petitions rose from 521 to 1,172 during Russia's war against Ukraine.

The 2023 report (printed paper 20/11600), handed over on 26 June 2024, recorded 11,410 petitions, 1,832 fewer than in 2022. Labour and social affairs (1,516) and the interior ministry (1,506) outranked health (1,195), and 7,661 cases, about 67 percent, were individual complaints. The committee met 29 times and held six public sittings on ten petitions. From 1 July 2024 it cut the public-hearing quorum from 50,000 co-signatures in four weeks to 30,000 in six weeks. The governing SPD, Greens and FDP, with the AfD and the Left group, voted in favour; the CDU/CSU called the change a minor reform. Stamm-Fibich told the plenary the next day that it was the first substantial revision since electronic petitions about twenty years earlier.

Hearings and notable petitions

The first public sitting she chaired, on 14 February 2022, heard three petitions over the threshold. Daniel Loy asked for information, care and research on myalgic encephalomyelitis/chronic fatigue syndrome, which he linked to long COVID; Charité immunologist Carmen Scheibenbogen called announced funding insufficient, and health state secretary Sabine Dittmar cited planned competence centres. The committee later unanimously recommended referring it to the federal government zur Berücksichtigung, its strongest recommendation, while calling the measures taken still inadequate.

Petra Reis-Berkowicz, for Bavarian statutory-health-insurance physicians, asked for a longer test of the electronic prescription; Dittmar said the rollout set for 1 January 2022 had been postponed. Gohdar Alkaidy asked the Bundestag to recognise the Islamic State's 2014 attacks on the Yazidis as genocide. In the June 2023 debate, Sabine Weiß (CDU/CSU) said the committee had unanimously recommended consideration and that the Bundestag had then recognised the genocide unanimously.

In 2022 seven public sittings covered twelve petitions. The most supported sought to continue the Sprach-Kitas language programme (250,759 co-signatures) and to reject a general coronavirus vaccination mandate (133,556). In 2023 the largest, with 544,963 co-signatures, came from Andreas Gassen, chair of the National Association of Statutory Health Insurance Physicians, on conditions for outpatient care. Heard on 19 February 2024 with Health Minister Karl Lauterbach present, it sought an end to practice budgets and recourse claims; Lauterbach pointed to a planned care bill, while Gassen said office-based care was near a tipping point. Other public petitions that year concerned balcony solar units (102,111 co-signatures) and liquefied-natural-gas terminals off Rügen (94,770).

Work outside health policy

Economy, foreign affairs and development

Outside the Health Committee, Martina Stamm-Fibich's seats in the Bundestag were substitute memberships. In the 19th term the archived biography records her as a substitute on the Committee on Economic Affairs and Energy and on the Subcommittee on Global Health. In the 20th term it lists her, from 26 October 2021 to 25 March 2025, as a substitute on the Committee on Economic Cooperation and Development and on the Foreign Affairs Committee.

The parliamentary groups nominate full members and their substitutes. A substitute may attend, but may vote and move a motion only when representing an absent full member of the same group. The Foreign Affairs Committee is closed. As with the Defence Committee, admission is limited to a defined circle that includes full members and their substitutes, and it does not sit in public.

On 6 November 2024 the development committee's minutes list her among the substitutes of the Social Democratic Party of Germany (SPD). Other SPD members are the rapporteurs for that day's economic-partnership agreements and a motion on development cooperation, and no speech is attributed to her. The minutes of 4 December 2024 list her and mark her absent.

Local government and other public roles while an MP

Disclosures for all three terms list an unpaid seat on the district council of Erlangen-Höchstadt. She was returned for the SPD on 16 March 2014 in third place, with 23,544 votes (13 of 60 seats for the SPD), and again on 15 March 2020 with 26,066 votes, the most on a list that won eight seats; that notice called her a member of the Bundestag. The same day she was the SPD candidate for district administrator. The Bavarian State Office for Statistics recorded 8,295 votes (11.6 percent) for her; Alexander Tritthart of the Christian Social Union in Bavaria was elected on the first ballot with 40,310 votes (56.4 percent). Until February 2016 she was also an unpaid member of the municipal council of Möhrendorf.

From 30 November 2021 the disclosures list the advisory board on fundamental savings-bank policy (Beirat für sparkassenpolitische Grundsatzfragen) of the Sparkassenverband Bayern. The association describes it as a cross-party forum of Bavarian members of the European Parliament, the Bundestag and the Landtag of Bavaria. Under the statute the administrative council may appoint such boards, including outsiders, to advise on fundamental policy or scientific questions./1/(v)/3/(f)/SVB-Satzung.pdf) Published gross receipts were 2,500 euro plus 800 euro in 2022 and 2,500 euro plus 1,200 euro in 2023, figures the members' code defines as gross amounts, including benefits in kind and before the member's own expenses, not as taxable income.

The biographies she supplied list membership of IG Metall. On her abgeordnetenwatch profile she wrote that her works-council work and her IG Metall engagement shaped her political aims on co-determination and collective bargaining. The 20th-term disclosures also list an unpaid post as deputy chair of the presidium of the Arbeiterwohlfahrt district association for Upper and Middle Franconia.

After the Bundestag

The appointment

On 9 February 2026 the Siemens-Betriebskrankenkasse (SBK), a company health-insurance fund in Germany's statutory system, announced that Martina Stamm-Fibich would head its political staff unit, the Stabsstelle Politik. The fund said the post covered its political positioning and its dialogue with decision-makers at federal and state level.

She had been a member of the Bundestag for the Social Democratic Party of Germany (SPD) from 2013 to 2025, sitting on the Health Committee and, at the end of that period, chairing the Petitions Committee. She stood again in the 2025 German federal election and was not returned. Before parliament she had spent years at Siemens, in corporate communications and as a works council member released from her ordinary duties. The fund's notice tied that record to workplace co-determination and to the day-to-day practice of company health funds.

In the statement issued with the appointment she said that long employment in a large industrial firm had shaped her regard for company health funds, and that the same experience had "lastingly influenced" her health-policy work. She said she wanted to bring that view to the SBK so as to represent insured persons "clearly, in a practical way and effectively" in political dialogue. The notice itself said she brought perspectives from politics and from that earlier employment to the representation of the insured. The fund's website later listed her among its contacts for politics.

The staff post was separate from an honorary welfare role she had already taken. At a district conference in the Nuremberg Press Club in April 2025, delegates of the Arbeiterwohlfahrt for Upper and Middle Franconia elected her chair of the honorary presidium with 73 percent of the vote, succeeding Rudolf Schober. She said she was glad, after her active time in the Bundestag, to take the chair.

How the move was reported

Trade coverage on the day of the announcement cast the change as a move from making health policy to speaking for a payer. The Pharmazeutische Zeitung recalled her, for a pharmacy readership, as a critic of "pharmacy without a pharmacist" — the traffic-light coalition's idea that pharmacy technicians could stand in for a pharmacist — and as the SPD group's rapporteur on medicines and on remedies and aids. It reported that she was now putting her health-policy experience at the SBK's disposal, as the fund had said that day. The Deutsche Apotheker Zeitung headlined her takeover of the political staff and summed up the step as a former SPD health politician now representing a health insurer's interests; the caption on its photograph said she was leading the fund's political communication.

Apotheke Adhoc used the headline that the SPD politician was becoming a lobbyist for statutory health insurance. It listed her as the SPD group's patient representative from 2018 and as rapporteur on pharmaceuticals and medical devices, remedies and aids, the Federal Joint Committee, patient counselling and health-related consumer protection, then printed her statement on company funds. Monitor Versorgungsforschung, on 10 February, largely carried the fund's text, including the fund's closing assertion that with her the political unit was experienced, politically well connected and oriented to insured persons' interests.

Regional reporting named the change more directly as lobbying. On 13 February the Nürnberger Nachrichten, in an article by Markus Hörath, headlined that the former member from the Erlangen area was "moving into the lobby camp." Its summary said she was leaving politics for that camp and bringing experience from Bundestag committees to the SBK.

Personal life

Family and residence

Martina Stamm-Fibich was born on 23 April 1965 in Erlangen. The archived biography for the 19th Bundestag (2017–2021) states that the biographical details rest on members’ own information, and in that text she is described as divorced, as having two children, and as evangelisch-reformiert (Reformed Protestant). The biography for the 20th term (2021–2025), likewise based on self-reporting, repeats the date and place of birth and the statement that she is divorced and has two children, but it does not repeat a religious affiliation. Neither biography names a spouse or the children.

The Federal Returning Officer’s February 2025 directory of Bundestag candidates gives her place of residence as 91096 Möhrendorf, in the district of Erlangen-Höchstadt, and her year and place of birth as 1965 in Erlangen. In that directory she appears for constituency 241 (Erlangen) and at place 26 on the state list of the Social Democratic Party of Germany (SPD) in Bavaria, with the occupation given as member of the German Bundestag.

Civic memberships

The 19th-term biography lists membership of IG Metall and the Arbeiterwohlfahrt (AWO). By the 20th term she was recorded as deputy chair of the presidium of the AWO district association for Upper Franconia and Middle Franconia, a role the Bundestag’s published disclosures describe as honorary, and as a member of IG Metall, the Arbeiter-Samariter-Bund (ASB), the VdK and the supporters’ association of the Technisches Hilfswerk in Erlangen (Förderverein THW Erlangen). The same biography enters her languages as “Englisch (f)”; in Kürschners Volkshandbuch for the Bundestag, the marker “f” means fluent.

On 5 April 2025 the AWO association for Upper and Middle Franconia held its district conference in Nuremberg, in the marble hall of the Presseclub, and elected her chair of the presidium. The association reported that she received 73 percent of the delegate votes, ahead of one other candidate, and succeeded Rudolf Schober, who had led the presidium for 20 years and did not stand again. She had been one of the deputy chairs. Delegates also elected Inge Aures (Kulmbach), Rainer Mosandl (Middle Franconia-South) and Dr. Detlef Classe (Nuremberg) as deputies. The twelve-member presidium is honorary and was chosen for four years. After the vote she said she had been closely connected with the AWO in Upper and Middle Franconia for decades.

Evidence & methodology

How the record is sourced and how the score is derived.

The score is formula-derived (Factrail formula v1, version 1.0.0), not an editorial verdict. Read the methodology.

By the · Method: how we source and score · Last reviewed

Dispute a fact on this pageNamed here, or represent someone who is? Request a right of reply.